Core Viewpoint - The company held its 2024 annual performance briefing, addressing investor concerns about its core product, Panlong Qipian, and its strategies to mitigate price reduction risks from centralized procurement [1][2] Group 1: Company Performance and Product Positioning - Panlong Qipian is an exclusive patented traditional Chinese medicine and a Class A product under medical insurance, recognized in multiple national clinical guidelines and textbooks [1] - In the first half of 2024, Panlong Qipian ranked first in market share within the traditional Chinese medicine sector for musculoskeletal and rheumatic diseases, holding an 8.05% market share [1] - The company has developed a strong portfolio of products for rheumatic bone diseases, including Panlong Qipian, Panlong Jiu, and others, enhancing its market presence and competitiveness [1] Group 2: Strategic Initiatives and Future Development - The company plans to deepen evidence-based research on Panlong Qipian, enhance its competitive strategies, and actively develop untapped markets, particularly in county-level areas [2] - Future potential products, such as Xiaer Yanbian Granules and Bone Health Tablets, are expected to exceed one billion in market development, aiming for a dual sales drive in clinical and retail sectors [2] - The company will leverage its full industry chain advantages to strengthen its drug source base and accelerate innovation in traditional Chinese medicine [2]